Key result
Surgical resection achieves ~55% overall survival in pediatric ACC, declining with age and advanced stage.
Why the study?
Pediatric adrenal cortical carcinoma is a rare heterogeneous cancer that is incompletely understood and differs from its adult counterpart, with overall survival remaining poor.
Pediatric ACC is a distinct clinical and molecular entity from adult ACC, necessitating pediatric-specific diagnostic scoring and genetic screening for cancer predisposition syndromes.
Answers are grounded in this paper and cite their sources.
Survival data from resection in pediatric ACC guide prognostic discussions; leaves open validation in prospective cohorts and integration with molecular profiling.
Pediatric adrenal cortical carcinoma (ACC) is a rare heterogeneous cancer type that is incompletely understood and differs from its adult counterpart in clinical presentation, histopathological characteristics, genomic landscape, and prognosis. Pediatric ACC has a bimodal age distribution for children with ACC, with the highest incidence in young children and adolescents. Tumors commonly present with an endocrine syndrome such as virilization or Cushing’s syndrome, associated with hormone overproduction. Surgical resection is the primary treatment. Adjuvant therapies such as mitotane or chemotherapy can lead to (severe) side effects in children and should be closely monitored. Histopathological assessment commonly relies on the AFIP/Wieneke classification, with the modified reticulin algorithm also providing predictive value. Recently, the two-step scoring system by Picard aimed to integrate the AFIP/Wieneke classification and the Children’s Oncology Group (COG) staging system into a two-step model. Molecularly, pediatric ACC is strongly associated with germline variants of TP53 and loss of heterozygosity of chromosomes 11 and 17. Somatic variants in several genes, including ATRX and CTNNB1, have been identified and are associated with poor prognosis. Multiple factors, such as age, tumor size, and biomarkers, with Ki67-labeling index being most important, are of prognostic value. Despite research advances, overall survival remains poor and worsens with older age at diagnosis and advanced disease. To improve survival rates of pediatric ACC further research is necessary aiming at optimizing therapeutic strategies in these patients. This review summarizes current knowledge of this challenging tumor and highlights recent advances in the field.
No takes yet. Share an insight, caveat, or question.
Swart et al. (2026) conducted a review in Pediatric patients with adrenocortical carcinoma (ACC), including children under 4 years and adolescents with ACC, many with germline TP53 variants or cancer predisposition syndromes such as Li-Fraumeni syndrome and Beckwith-Wiedemann syndrome. Surgical resection with or without adjuvant therapies such as mitotane and chemotherapy vs. No adjuvant therapy or placebo (historically) was evaluated on Overall survival (OS) or progression-free survival (PFS) at 3 years or 5 years. Surgical resection achieves approximately 55% 3-year overall survival in pediatric ACC patients, with survival declining in advanced stages and older age at diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: